Publications
2 shownMolecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC
ABSTRACT Lonafarnib, an oral antiviral that targets the fusion glycoprotein of respiratory syncytial virus (RSV), has demonstrated efficacy in vitro and in vivo . However, becau...
Frequent Co-Authors
Researcher Info
- h-index
- 0
- Publications
- 2
- Citations
- 0
- Institution
- Guangxi Medical University
External Links
Identifiers
- ORCID
- 0000-0001-6492-9511
Impact Metrics
h-index
0
h-index: Number of publications with at least h citations each.